Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Boehringer Ingelheim's adalimumab biosimilar, Cyltezo, approved in E.U.

Nov. 15, 2017

Dosing begins in first-in-human phase Ib study of DEN-181

Nov. 15, 2017

Clinical progress reported for Pfizer's IRAK-4 inhibitor PF-06650833

Nov. 15, 2017

Phase I results reported for Bristol-Myers Squibb candidate for autoimmune diseases

Nov. 14, 2017

Five Prime, GlaxoSmithKline present novel neighbor of punc e11 polypeptides

Nov. 13, 2017

Novel retinoid RORgammaT receptor modulators identified at Janssen

Nov. 10, 2017

Synermore compares safety and pharmacokinetics of SYN-060 to Humira

Nov. 9, 2017

FDA grants orphan drug designation to arimoclomol for inclusion body myositis

Nov. 8, 2017

FDA awards rare pediatric disease designation to ArQule's miransertib

Nov. 2, 2017

First patient enrolled in phase III trial of piclidenoson in rheumatoid arthritis

Oct. 31, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...